Cell>Point Executes China License with United Eastern Pharmaceutical for Oncardia for Cancer and Heart Disease Diagnostic Imaging

CENTENNIAL, Colo., June 16, 2016 – Cell>Point today announced that it has entered into an exclusive license agreement for China, Hong Kong and Macau with United Eastern Pharmaceutical (UEP), a company representing a consortium from the U.S. and China.

The license agreement covers Cell>Point’s diagnostic radiopharmaceutical Oncardia (ethylenedicysteine-glucosamine) which was developed for labeling with technetium-99m for SPECT cameras or 68-gallium for PET cameras for imaging in cancer and cardiovascular disease. Oncardia is based on an ethylenedicysteine drug conjugate platform licensed by Cell>Point from The University of Texas M.D. Anderson Cancer Center. The license with UEP provides for Cell>Point to receive an upfront payment, regulatory milestone payments as well as royalties on sales. Cell>Point will be seeking regulatory approval from the China FDA to expand its Phase 3 lung cancer imaging trial to include clinical sites in China. The parties have agreed that when the current cardiovascular study reaches Phase 3, Cell>Point will include China clinical sites as part of the study.

According to Haoran Xi, CEO of UEP, “China needs affordable and accessible diagnostic molecular imaging to reach a substantially larger universe of people than is presently the case with the current standard of care. Plans are to pursue approvals in diagnosing and staging lung, head and neck, colorectal, breast, liver, stomach, lymphoma and other cancers in addition to diagnosing the presence and extent of cardiac ischemia. Oncardia can be used to assess the patient’s response to therapy while undergoing therapy. This will give oncologists a valuable tool to determine if the patient is benefiting from the selected therapy or should the oncologist reconsider the choice of therapy. The Chinese Central Government is implementing programs to improve the quality of medical care throughout the country. Cancer and vascular disease are the leading causes of death in China.”

Oncardia was developed to address the limitations of FDG-PET in cancer imaging while increasing access to cancer imaging to a significantly greater number of hospitals worldwide. Cell>Point is completing a Phase 3 trial for Oncardia in lung cancer under a Letter of Agreement with the FDA pursuant to a Special Protocol Assessment, and a Phase 2b cardiovascular trial in patients with coronary artery disease. The focus in cardiology is to assess the patient’s ischemia in a rest only imaging procedure which will
dramatically shorten the time required to complete the patient’s study and achieve noticeably greater diagnostic accuracy compared to the standard of care. “We are pleased to be working with UEP as our long term partner in China and are confident that UEP will be instrumental in helping to build a consensus of support for Oncardia among the country’s nuclear medicine community and network of hospitals”, according to Greg Colip, CEO of Cell>Point.

About Cell>Point, L.L.C.

Cell>Point is a biopharmaceutical company focused on the development of universal molecular imaging compounds and molecular therapeutics for the diagnosis, staging, treatment and treatment monitoring of cancer, cardiovascular disease, and a range of ischemic diseases. Cell>Point has exclusive licenses to five drug-development platforms, all from The University of Texas MD Anderson Cancer Center in Houston, a world leader in cancer research and care. Information on Cell>Point’s product candidates and licenses, recent press releases, and patents and patent filings can be obtained through its website at www.cellpointweb.com. The Company has offices in Centennial, Colo. and Houston, Texas.
About United Eastern Pharmaceutical

United Eastern Pharmaceutical (UEP), formerly TDD, Inc., is a Houston, Texas based cross-industry group whose focus is investment in energy and pharmaceutical development. UEP, together with a consortium of partners based in Tianjin, will be responsible for the clinical development, regulatory approval, marketing and distribution in China (including Hong Kong and Macau) of Cell>Point’s novel nuclear medicine imaging product Oncardia for cancer and cardiovascular disease.

3 Responses to Cell>Point Executes China License with United Eastern Pharmaceutical for Oncardia for Cancer and Heart Disease Diagnostic Imaging

  • The license with UEP provides for Cell Point to receive an upfront payment and regulatory milestone payments as well as royalties on sales.

  • Jessiecew says:

    A Biological Masterpiece, But Subject to Many Ills
    The human foot is a biological masterpiece. Its strong, flexible, and functional design enables it to do its job well and without complaint—if you take care of it and don’t take it for granted.
    healthThe foot can be compared to a finely tuned race car, or a space shuttle, vehicles whose function dictates their design and structure. And like them, the human foot is complex, containing within its relatively small size 26 bones (the two feet contain a quarter of all the bones in the body), 33 joints, and a network of more than 100 tendons, muscles, and ligaments, to say nothing of blood vessels and nerves.

  • Robertpaimi says:

    Doctor Who is now considered a British Institute and has come a long way since it first aired on November 23rd 1963. The very first show saw the Doctor travel 100,00 years into the past to help some dim cavemen discover light. After 26 seasons and seven Doctors later the series came off our screens in 1989 much to the disappointment of the huge devoted fanbase. In 1996 an attempt was made to revive Doctor Who but it wasnt until June 2005 when it came back with a vengeance with Christopher Eccleston as the ninth Doctor that put the series back on the map as it were. It then went on for 5 years with David Tenant portraying the Doctor until 2010 when Matt Smith took over the role. Today it is still a great family show and has attracted many new fans.

Leave a Reply

Your email address will not be published.